Discontinuation of aspirin as primary prevention and cardiovascular events in diabetes

Completed

• Conditions: Diabetic patient at risk of atherosclerotic cardiovascular disease; Aspirin discontinuation; Diabetes mellitus; primary prevention

• Registration Number: TCTR20220114002
• Lead Sponsor: /A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-12-31
• Study Start: 2022-01-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 298

Inclusion Criteria

Thai male and female residents with 45 years of age will be conducted in Khon Kaen Hospital

Exclusion Criteria

1. All patients with diagnostic records of prior cardiovascular events
2. Current antithrombotic users
3. Patients whose domicile are not in Muang district of Khon Kaen province will also be excluded due to lack of accessible medication history, p

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Aspirin discontinuation Up to 3 years before the index date Discontinuation of aspirin or lost to follow-up after usage of aspirin as primary prevention

Secondary Outcome Measures

Name	Time	Method
Aspirin non-adherence Up to 3 years before the index date Patients with history of aspirin prescription with lower than 80% medication possession ratio within the recorded period measured using rates of prescription refill method